Comparison
Pasireotid vs. Teduglutid
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Research other
CAS no.
396091-73-9
197922-42-2
Molecular weight
1047.21 g/mol
3752.13 g/mol
Half-life
no data
no data
Sequence
no data
no data
Mechanism of action
Pasireotid
Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.
Teduglutid
Teduglutide activates the GLP-2 receptor, promoting growth and regeneration of small-intestinal villi, increasing nutrient and fluid absorption and thereby reducing dependence on parenteral nutrition. The glycine substitution at position 2 makes it resistant to rapid breakdown by DPP-4.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
1
2
of which in humans
1
2
Effects recorded
2
2
Open conflicts
0
0
Documented adverse events
2
2
Legal status
Full entries
Frequently asked questions
- What is the difference between Pasireotid and Teduglutid?
- Pasireotid is classified as "Research other", while Teduglutid is classified as "Research other". Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. Teduglutid: Teduglutide is a DPP-4-resistant analog of GLP-2 (glucagon-like peptide-2). It promotes growth and function of the intestinal mucosa and is approved for treating short bowel syndrome. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Pasireotid or Teduglutid?
- The highest available evidence level is "Human RCT" for Pasireotid and "Human RCT" for Teduglutid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Pasireotid and Teduglutid in Germany and the United States?
- Germany: Pasireotid — Prescription, Teduglutid — Prescription. United States: Pasireotid — Prescription, Teduglutid — Prescription. These are factual summaries with source and review date on the individual pages.